From the Journals
From the Journals
Rivaroxaban linked to more bleeding compared with dabigatran in elderly patients with nonvalvular AF
Rivaroxaban is associated with significantly more intra- and extracranial bleeding than is dabigatran in older patients who have nonvalvular...
From the Journals
No increase in CV events with long-acting bronchodilators in COPD
Long-acting bronchodilators do not appear to increase the risk of cardiovascular events in the first year of use in individuals with chronic...
From the Journals
Influenza vaccine highly beneficial for people with type 2 diabetes
Seasonal influenza vaccinations can significantly decrease the chances of hospitalizations for stroke, heart attack, and other cardiovascular...
From the Journals
Has mystery of exercise-intolerant chronic thromboembolic disease been solved?
Key clinical point: This study identifies key clinical features of the pathophysiology of exercise intolerance in chronic thromboembolic disease (...
From the Journals
Whole brain radiotherapy not beneficial for NSCLC metastasis
Whole brain radiotherapy provided no clinically significant benefit for most patients with metastatic non–small-cell lung cancer.
From the Journals
Pneumonitis with nivolumab treatment shows common radiographic patterns
Among 20 cancer patients treated with this PD-1 inhibitor who developed pneumonitis, cryptogenic organizing pneumonia was seen in 13.
From the Journals
IASLC lung cancer staging project proposes changes for new TNM classification
Key clinical point: New lung cancer classification to become effective January 2017. Major finding: Size will now be a descriptor in all T...
From the Journals
Wanted: Better evidence on fast-track lung resection
Key clinical point: Well-designed clinical trials are needed to determine the effectiveness of fast-track recovery pathways in lung resection.
From the Journals
NSQIP calculator shown inadequate to stratify risk in stage I non–small cell lung cancer.
Key clinical point: The current NSQIP Surgical Risk Calculator does not adequately estimate risk among patients with clinical stage I non–small...
From the Journals
Alectinib shows promise in crizotinib-refractory ALK-rearranged NSCLC
Key clinical point: Alectinib, an oral, small molecule inhibitor of ALK, showed promising clinical activity in crizotinib-refractory patients with...